Drugs Made in America (NASDAQ: DMAA) details new CEO pay deal
Rhea-AI Filing Summary
Drugs Made In America Acquisition Corp. reported new executive compensation arrangements. On April 22, 2026, it signed an updated Statement of Work with Titan Advisory Services, which supplies Chief Financial Officer services from Saleem Elmasri under a consulting structure.
The prior consulting terms included $3,500 in monthly compensation and a grant or transfer of 100,000 ordinary shares to Mr. Elmasri upon engagement. On the same date, the company also entered into a CEO Compensation Agreement with Aleutian Equity Holdings LLC, the designated compensation vehicle for Chief Executive Officer Roger E. Bendelac, including customary indemnification and limitation-of-liability provisions.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
CFO monthly consulting fee: $3,500 per month
CFO share grant: 100,000 ordinary shares
CFO appointment date: November 17, 2025
+2 more
5 metrics
CFO monthly consulting fee
$3,500 per month
Compensation to Titan Advisory Services LLC for CFO services
CFO share grant
100,000 ordinary shares
Granted or transferred to Saleem Elmasri upon engagement
CFO appointment date
November 17, 2025
Saleem Elmasri appointed Chief Financial Officer
CEO appointment date
February 28, 2026
Roger Bendelac appointed Chief Executive Officer
Agreement execution date
April 22, 2026
Updated SoW and CEO Compensation Agreement signed
Key Terms
Material Definitive Agreement, Master Services Agreement, Statement of Work, indemnification, +1 more
5 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Master Services Agreement financial
"entered into a Master Services Agreement (the “Consulting Agreement”)"
A master services agreement is a standing contract that sets the main terms, responsibilities, pricing framework and processes for future work between two parties, allowing individual projects or orders to be added later without renegotiating core terms. For investors, it signals predictability and reduced legal friction around revenue streams and costs—like a subscription plan for services that makes future income and obligations easier to forecast and value.
Statement of Work financial
"The Consulting Agreement included a Statement of Work (the “SoW”)"
A statement of work (SOW) is a written agreement that spells out what work will be done, who will do it, when it will be finished, how success is measured, and how payment will be handled. Think of it as a detailed recipe and timeline for a project that both sides sign off on. For investors, an SOW matters because it creates predictable revenue and obligations, clarifies milestones and risks, and helps assess whether a company can deliver on contracts and meet financial forecasts.
indemnification financial
"The CEO Compensation Agreement also includes customary provisions regarding indemnification"
A contractual promise to cover losses, expenses, or legal claims that arise from specified events, such as breaches of representations or third‑party lawsuits. For investors, indemnification matters because it shifts potential financial risk and future cash outflows from one party to another, similar to a friend agreeing to pay your bill if you’re sued, and can affect deal value, expected returns, and contingent liabilities on the balance sheet.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive agreements did DMAA disclose in this 8-K filing?
Drugs Made In America Acquisition Corp. disclosed an updated Statement of Work for CFO services and a new CEO Compensation Agreement. Both were signed on April 22, 2026 and formalize how external entities are engaged to provide the company’s principal financial officer and chief executive officer services.
How is the CFO of DMAA compensated under the consulting arrangement?
The consulting framework for CFO Saleem Elmasri includes $3,500 in monthly compensation and 100,000 ordinary shares upon engagement. These terms are provided through Titan Advisory Services LLC under a Master Services Agreement and related Statement of Work previously approved by Drugs Made In America Acquisition Corp.
Who provides Chief Financial Officer services to DMAA?
Chief Financial Officer services are provided by Saleem Elmasri through Titan Advisory Services LLC under a Master Services Agreement. An updated Statement of Work, dated April 22, 2026, governs the scope of services and follows earlier disclosed terms including monthly cash compensation and an ordinary share grant upon engagement.
How is DMAA’s CEO Roger Bendelac compensated under the new agreement?
Drugs Made In America Acquisition Corp. entered a CEO Compensation Agreement with Aleutian Equity Holdings LLC, the designated compensation vehicle for CEO Roger E. Bendelac. The agreement covers his compensation framework and includes customary provisions on indemnification, limitation of liability, dispute resolution, and governing law.
When were DMAA’s current CFO and CEO appointed?
Drugs Made In America Acquisition Corp. appointed Saleem Elmasri as Chief Financial Officer on November 17, 2025 under a consulting structure. Roger Bendelac was appointed Chief Executive Officer on February 28, 2026, with his specific compensation terms later set in an agreement dated April 22, 2026.